ProteoNic Biosciences, a leading provider of premium vector technology and services for the production of biologics, has launched its highly anticipated LV-2G UNic Early Access Program. This programme marks a significant milestone in lentivirus manufacturing optimization, offering access to groundbreaking vector technology designed to revolutionize viral vector production.

Following the recent launch, ProteoNic extends an invitation to CDMOs, biotechs, and biopharmaceutical companies to experience firsthand the transformative potential of LV-2G UNic. By seamlessly integrating this vector technology into existing systems, participants can achieve remarkable enhancements in titers, paving the way for increased viral vector production capacity and substantial improvements in manufacturing cost efficiency.

Frank Pieper, CEO of ProteoNic, commented: “The LV-2G UNic Early Access Program will serve as a launching platform for our viral vector manufacturing innovation. By offering early access to our state-of-the-art vector technology, we empower researchers to unlock unprecedented levels of efficiency and productivity in viral vector manufacturing.”

LV-2G UNic represents next generation vector technology, engineered to elevate lentiviral titers across a wide array of expression systems. The technology drives enhanced infectious viral particle production, by providing a significant boost in gRNA production through increased transcription levels achieved with ProteoNic’s patented Dual Promoter system.

Participation in the LV-2G UNic Early Access Program offers exclusive benefits, including access to ProteoNic’s cutting-edge LV-2G UNic vector technology, optimizing lentiviral particle expression and co-development opportunities. This technology can be seamlessly integrated into current workflows with minimal to no process development required.

For more information about LV-2G UNic and the Early Access Program, visit: www.proteonic.nl